CA-125
You don't need to be Editor-In-Chief to add or edit content to WikiDoc. You can begin to add to or edit text on this WikiDoc page by clicking on the edit button at the top of this page. Next enter or edit the information that you would like to appear here. Once you are done editing, scroll down and click the Save page button at the bottom of the page.
| mucin 16, cell surface associated
| |
| Identifiers | |
| Symbol | MUC16 |
| Entrez | 94025 |
| HUGO | 15582 |
| OMIM | 606154 |
| RefSeq | NM_024690 |
| UniProt | Q8WXI7 |
| Other data | |
| Locus | Chr. 19 p13.2 |
|
WikiDoc Resources for CA-125 | |
|
Articles | |
|---|---|
|
Media | |
|
Evidence Based Medicine | |
|
Clinical Trials | |
|
Ongoing Trials on CA-125 at Clinical Trials.gov Clinical Trials on CA-125 at Google
| |
|
Guidelines / Policies / Govt | |
|
US National Guidelines Clearinghouse on CA-125
| |
|
Books | |
|
News | |
|
Commentary | |
|
Definitions | |
|
Patient Resources / Community | |
|
Directions to Hospitals Treating CA-125 Risk calculators and risk factors for CA-125
| |
|
Healthcare Provider Resources | |
|
Continuing Medical Education (CME) | |
|
International | |
|
| |
|
Businness | |
|
Experimental / Informatics | |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Phone:617-525-6884
Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [2] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.
Overview
CA-125, also known as CA125, is an abbreviation for cancer antigen 125. CA-125 is a tumor marker or biomarker that may be elevated in the blood of some people with specific types of cancers. CA-125 is a mucinous glycoprotein and the product of the MUC16 gene.
Specificity and sensitivity
It is best known as a marker for ovarian cancer, but it may also be elevated in other malignant cancers, including those originating in the endometrium, fallopian tubes, lungs, breast and gastrointestinal tract.
CA125 may also be elevated in a number of relatively benign conditions, such as endometriosis,[1] several diseases of the ovary, and pregnancy.[1] It also tends to be elevated in the presence of any inflammatory condition in the abdominal area, both cancerous and benign.
Thus, CA-125 is not perfectly specific for cancer nor is it perfectly sensitive since not every patient with cancer will have elevated levels of CA-125 in the blood.[1] For example, 79% of all ovarian cancers are positive for CA125, whereas the remainder do not express this antigen at all. [citation needed]
Use
CA-125 is clinically approved for following the response to treatment and predicting prognosis after treatment. It is especially useful for detecting the recurrence of ovarian cancer. Its potential role for the early detection of ovarian cancer is controversial and has not yet been adopted for widespread screening efforts in asymptomatic women. The key problems in using the CA-125 test as a screening tool are its lack of specificity and its inability to detect early stage cancers. An operation would be necessary to confirm that a woman with elevated CA-125 has ovarian cancer, with the associated risk of death from major surgery. In addition, even if cancer was confirmed in such circumstances, it usually would be at an advanced stage where therapy is less effective. The goal of many cancer biologists is to develop a test that would be employed to diagnose ovarian cancer at an early stage, when the effects of therapeutic interventions are optimal.
History
CA-125 was initially detected using the monoclonal antibody designated OC125. Dr.'s Robert Bast, Robert Knapp and their research team first isolated this monoclonal antibody in 1981.[1]
Ranges in ovarian cancer
While this test is not generally regarded as useful for large scale screening by the medical community, a high value may be an indication that the woman should receive further diagnostic screening or treatment. Normal values range from 0 to 35 (u/mL). Elevated levels in post-menopausal women are usually an indication that further screening is necessary. In pre-menopausal women, the test is less reliable as values are often elevated due to a number of non-cancerous causes, and a value above 35 is not necessarily a cause for concern.
See also
References
See also
- CA-125 blood test urban legend at snopes.com
hr:Karcinomski antigen 125 ms:CA-125
Acknowledgement and Attribution Regarding Sources of Content
Some of the initial content on this page may be incorporated in part from copyleft sources in the public domain including wikis such as Wikipedia and AskDrWiki. Drug information for patients came from the The National Library of Medicine. Infectious disease information may have come from the Centers for Disease Control (CDC). Differential Diagnoses are drawn from clinicians as well as an amalgamation of 3 sources: 1.The Disease Database; 2. Kahan, Scott, Smith, Ellen G. In A Page: Signs and Symptoms. Malden, Massachusetts: Blackwell Publishing, 2004:3; 3. Sailer, Christian, Wasner, Susanne. Differential Diagnosis Pocket. Hermosa Beach, CA: Borm Bruckmeir Publishing LLC, 2002:7 .
